Marshall Protocol for Autoimmune Disease

Is one man's radical cure for autoimmune disease reality or quackery?

HEALTH With autoimmune diseases, the immune system mistakes some part of the body as a pathagen and attacks it. The breadth of autoimmune disease is vast enough to mimmic or cause many ailments, including arthritis and multiple sclerosis. Treatment generally involves immunosuppression and addressing symptoms.

The Marshall Protocol (MP), named after Dr. Marshall Trevor, is based on the hypothesis that chronic diseases (termed Th1 illnesses), are the result of infection by an intraphagocytic, metagenomic microbiota of chronic bacterial forms that are often referred to as the Th1 pathogens. The term intraphagocytic refers to the fact that these bacteria have developed the ability to remain alive and proliferate undetected inside the cytoplasm of the cells they infect. These cells include macrophages, the very cells of the immune system that the body uses to kill invading pathogens. Once inside these cells, they cause our own cells to release inflammatory cytokines (proteins that often generate pain and/or fatigue).

The Marshall Protocol is a phase II community-based internet medical study that is monitored by the FDA and used by physicians worldwide to treat a variety of chronic inflammatory and autoimmune diseases. These include (but are not limited to):

  • Sarcoidosis
  • Chronic Fatigue Syndrome
  • Fibromyalgia
  • Chronic Lyme Disease
  • Rheumatoid Arthritis
  • Multiple Chemical Sensitivity (MCS)
  • Myasthenia gravis
  • Psoriasis
  • Osteoarthritis
  • Hashimoto's Thyroiditis
  • Uveitis
  • Cardiac Arrhythmia

Apart from the symptoms or diagnosis indicating Th1 disease, the easiest way to find out if the Marshall Protocol may be applicable to a particular disease is to get a blood test and check the level of D Metabolites. This test can detect the elevated level of 1,25-D often seen in patients with chronic disease, but must be done correctly in order to be of any value.

The Marshall Protocol uses five different antibiotics to target a much wider spectrum of bacteria than minocycline alone. These antibiotics are also taken 3 at a time in the later phases of the protocol. This means that they are better able to weaken the bacteria that cause inflammatory diseases by blocking more of their ribosomes, or proteins they use to replicate, glean energy, etc. So basically, the Marshall Protocol allows patients to kill a much broader spectrum of bacteria while also giving their immune system a much greater capacity to get the job done. Patients on the MP also avoid vitamin D, a secosteroid that blocks the ability of the innate immune system to function up to par.

Trevor Marshall, Ph.D., is a biomedical researcher. In 2002, Marshall published a pathogenesis for sarcoidosis followed in 2004 by the definitive paper in Autoimmunity Reviews "Sarcoidosis Succumbs to Antibiotics" (PDF of slides). He has since written several papers and given numerous presentations that detail the pathogenesis of chronic disease. He has derived many of his findings by using molecular modeling.

Tags: clinical trial study, dermatologist, dermatology, diagnostic, endocrinology, immunology, microbiology, molecular biology, pulmonary, respiratory, rheumatology


For comprehensive information, see About the Marshall Protocol at Bacteriality.